Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib + sintilimab + SOX vs sintilimab + SOX as neoadjuvant therapy for resectable locally advanced gastric/GEJ adenocarcinoma (Phase II, China)
ChiCTR2600127362Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fruquintinib, sintilimab, oxaliplatin and tegafur + gimeracil + oteracil in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Pathological complete response rate (pCR). Planned start Jun 2026; status: not yet recruiting.
02
Drugs
fruquintinibsintilimaboxaliplatintegafur + gimeracil + oteracil
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600127362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127362.